Blue Water Biotech Appoints Board-Certified Urologist Jay Newmark, M.D., MBA as Chief Medical Officer
April 26 2023 - 2:44PM
Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a
biotechnology company spanning multiple sectors, today announced
the appointment of Jay Newmark, M.D., MBA as the Company’s Chief
Medical Officer.
Dr. Newmark is a board-certified urologist with over 30 years of
experience managing Men’s Health issues, including benign prostatic
hyperplasia (“BPH”). Blue Water currently owns ENTADFI®, an
FDA-approved treatment for BPH that counteracts negative sexual
side effects seen in men on alternative BPH therapies. Dr.
Newmark’s appointment will support Blue Water’s upcoming launch of
ENTADFI® and he will work closely with Blue Water management to
ensure BPH patients are able to receive proper access to
treatment.
In addition to his extensive medical training and experience in
urology private practice, Dr. Newmark has a strong background in
commercial product development in the Men’s Health sector.
Previously, Dr. Newmark served as Chief Medical Officer at Clarus
Therapeutics, Inc., where he was integral to the launch of JATENZO®
and other Men’s Health initiatives. He has also worked on advanced
detection technologies for prostate cancer at Genomic Health Inc.
and OPKO Health Inc.
“I am thrilled to join the Blue Water team and provide my
expertise as we prepare to launch ENTADFI® to support patients with
BPH,” said Dr. Newmark. “Millions of men suffer from BPH symptoms
each year and many of those men are faced with frustrating sexual
side effects as a result of their BPH medication. We look forward
to supporting new BPH patients with ENTADFI® as well as provide
current patients a novel option to address BPH symptoms without
sacrificing sexual performance as we see with other current
therapies.”
“The addition of Dr. Newmark to the Blue Water team is a
critical and exciting step in the execution of our commercial
strategy for ENTADFI®,” said Joseph Hernandez, Chairman and Chief
Executive Officer of Blue Water. “As we prepare to make this
product available to men with BPH across the country, we will rely
heavily on his knowledge and experience to support our commercial
operation and our patients. We are confident that his expertise
both in the medical field as a urologist and in the product
development space will be invaluable moving forward through launch
and beyond.”
Dr. Newmark received his M.D. from the University of Michigan
Medical School and completed his residency in urology at the Johns
Hopkins Hospital. He also holds a Master of Business Administration
from the University of Chicago.
Dr. Newmark will join Blue Water management at the upcoming
American Urological Association Annual Meeting 2023 from April 18th
through May 1st in Chicago, Illinois. Blue Water will be available
during the conference for one-on-one meetings and can be found at
booth 439. Interested parties may request a one-on-one meeting at
investors@bwbioinc.com or contact Blue Water at (513) 620-4101.
About ENTADFI®
ENTADFI® is an oral, once daily treatment for benign prostatic
hyperplasia ("BPH") that combines finasteride, a 5α-reductase
inhibitor, and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor,
offering a more effective treatment option compared to other
available therapies. Clinical trials have shown that ENTADFI® is
more effective in treating BPH symptoms, including urinary
frequency, urgency, weak stream, and difficulty initiating or
maintaining urination, compared to finasteride monotherapy.
Additionally, ENTADFI® has demonstrated a favorable safety profile,
with fewer adverse sexual side effects compared to finasteride.
ENTADFI® reduces potential for adverse sexual side effects, making
it a preferred choice for men seeking relief from BPH symptoms
without compromising their sexual health. ENTADFI® has received FDA
approval for the indication of initiating treatment of the signs
and symptoms of BPH in men with an enlarged prostate for up to 26
weeks. More information about BPH and full ENTADFI® prescribing
information can be found on the product website at
https://entadfipatient.com/.
About Blue Water Biotech
Blue Water Biotech, Inc. is a biotechnology company focused on
developing transformational therapies to address significant health
challenges globally. Headquartered in Cincinnati, OH, the Company
holds the rights to proprietary technology developed at the
University of Oxford, Cincinnati Children’s Hospital Medical
Center, St. Jude Children’s Hospital, and The University of Texas
Health Science Center at San Antonio. Blue Water is developing a
Streptococcus pneumoniae vaccine candidate, designed to
specifically prevent highly infectious middle ear infections, known
as acute otitis media (AOM), in children, and prevention of
pneumonia in the elderly. The Company is also developing a
universal flu vaccine that will provide protection from all
virulent strains in addition to licensing a novel norovirus (NoV)
S&P nanoparticle versatile virus-like particle (VLP) vaccine
platform from Cincinnati Children’s to develop vaccines for
multiple infectious diseases, including Marburg and monkeypox,
among others. Additionally, the Company is developing a Chlamydia
vaccine candidate with UT Health Science Center San Antonio to
prevent infection and reduce the need for antibiotic treatment
associated with contracting Chlamydia disease. Outside of its
vaccine franchise, Blue Water owns ENTADFI®, an FDA-approved, once
daily pill that combines finasteride and tadalafil for the
treatment of benign prostatic hyperplasia. This combination allows
men to receive treatment for their symptoms of BPH without the
negative sexual side effects typically seen in patients on
finasteride alone. For more information about Blue Water, visit
www.bwbioinc.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements may be identified by the use of
forward-looking words such as “anticipate,” “believe,” “forecast,”
“estimate,” “expect,” and “intend,” among others. These
forward-looking statements are based on Blue Water’s current
expectations and actual results could differ materially. There are
a number of factors that could cause actual events to differ
materially from those indicated by such forward-looking statements.
These factors include, but are not limited to, risks related to
Blue Water’s ability to realize the benefits of its acquisition of
ENTADFI®, risks related to BWV’s ability to expand its business
scope and its ability to commercialize ENTADFI®, risks related to
the development of Blue Water’s vaccine candidates; the failure to
obtain FDA clearances or approvals and noncompliance with FDA
regulations; delays and uncertainties caused by the global COVID-19
pandemic; risks related to the timing and progress of clinical
development of our product candidates; our need for additional
financing; uncertainties of patent protection and litigation;
uncertainties of government or third party payor reimbursement;
limited research and development efforts and dependence upon third
parties; and substantial competition. As with any vaccine under
development, there are significant risks in the development,
regulatory approval and commercialization of new products. Blue
Water does not undertake an obligation to update or revise any
forward-looking statement. Investors should read the risk factors
set forth in Blue Water’s Annual Report on Form 10-K, filed with
the Securities and Exchange Commission (the “SEC”) on March 9, 2023
and periodic reports filed with the SEC on or after the date
thereof. All of Blue Water’s forward-looking statements are
expressly qualified by all such risk factors and other cautionary
statements. The information set forth herein speaks only as of the
date thereof.
Media Contact Information:Blue Water Media
RelationsTelephone: (646) 942-5591 Email:
Nic.Johnson@russopartnersllc.com
Investor Contact Information:Blue Water Investor RelationsEmail:
investors@bwbioinc.com
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From Sep 2024 to Oct 2024
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From Oct 2023 to Oct 2024